AstraZeneca PLC (LSE:AZN) said a trial of its Imfinzi drug as an early treatment lung cancer immunotherapy administered with chemoradiotherapy (CRT) failed to make a statistically significant difference to patients.
Primary endpoint for the trial [PACIFIC -2] was progression-free survival (PFS) versus CRT alone for the treatment of patients with unresectable, stage III non-small cell lung cancer (NSCLC).
Susan Galbraith, executive vice president, oncology R&D, AstraZeneca, said: "Our goal with the PACIFIC-2 trial was to address a remaining unmet need for patients in this setting by introducing immunotherapy even earlier and concurrently administering Imfinzi with chemoradiotherapy.
“While today's results did not reach statistical significance, we will learn from this trial and we remain committed to improving patient outcomes by expanding the benefit of immunotherapy to lung cancer patients across treatment settings."
Imfinzi sequentially administered after platinum-based CRT is the established, global standard of care for the treatment of unresectable, Stage III NSCLC based on the results of the PACIFIC Phase III trial.
AstraZeneca has several ongoing registrational trials focused on testing Imfinzi in early stages of lung cancer, including in resectable NSCLC), medically inoperable or unresected Stage I-II NSCLC and unresectable, Stage III NSCL, and in limited-stage small-cell lung cancer.